Paragonix SherpaPak Cardiac Transport System is the only FDA cleared and CE marked device that safeguards hearts between donor and recipient patients
Paragonix Technologies, Inc. today announced AdventHealth (Orlando, Florida) has adopted its Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts for transplantation. A recent application of this innovative technology permitted the transport and preservation of a donor heart from nearly 1,000 miles away from AdventHealth’s transplant center in Orlando, Florida.
“As a successful high volume advanced heart failure and heart transplant center in Florida, our heart procurement teams are working around the clock to ensure our recipients on the waitlist receive a donor heart. We are thrilled about the addition of Paragonix SherpaPak™ Cardiac Transport System as a tool to provide best-in-class care of our transplant patients. Optimal preservation and quality management of the donor heart during transport from donor to recipient is paramount,” said cardiothoracic surgeon Dr. Scott Silvestry, Surgical Director of Thoracic Surgery at AdventHealth Transplant Institute in Orlando, Florida. “Furthermore, procuring a donor heart from extreme geographic distances requires utmost control of the process and monitoring of the preservation conditions of the heart in transport. Paragonix SherpaPak™ has made a typically uncontrolled process a highly controlled procedure with a permanent data record.”
“Our mission at OurLegacy is to maximize donor organ utilization and to provide the best quality donor organs to the transplant programs that we serve. We are excited about partnering with Dr. Silvestry and Barry Friedman RN, the Executive Director from AdventHealth Transplant Institute, to implement new standard-of-care technologies like Paragonix SherpaPak™ CTS,” said Virginia McBride, Director, OurLegacy OPO.
Paragonix SherpaPak™ CTS has been adopted or is being evaluated by over 20 major heart transplant centers in the United States and by over 15 European transplant centers. The device is currently marketed in the United States, the United Kingdom, Ireland, Switzerland, France, Spain, Italy, Germany, Austria, Sweden and the Slovak Republic in Europe.
“Patients on the waitlist for a donor heart face so many medical uncertainties. The preservation of the donor heart they are waiting for should not be one of them. We are thrilled to contribute a key tool to the transplant teams in giving their transplant recipients every possible advantage on their journey of receiving a donor heart,” said Bill Edelman, Chairman and CEO of Paragonix Technologies. “Elimination of preservation issues from the previously used method—like submerging transplant organs in an ice chest without any control over temperature or the inability to monitor—is translating into excellent clinical outcomes at our customers’ transplant programs.”
Source: Company Press Release